We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics


Drew Scientific manufactures and sells analytical instruments and reagents worldwide. Its product range includes cell... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Nov 2020 - 07 Nov 2020

Tortuosity-Powered Microfluidic Device Assesses Thrombosis

By LabMedica International staff writers
Posted on 18 Jun 2020
Print article
Image: The microfluidic device developed to help detect blood clots (Photo courtesy of Texas A&M College of Engineering).
Image: The microfluidic device developed to help detect blood clots (Photo courtesy of Texas A&M College of Engineering).
Accurate assessment of blood thrombosis and antithrombotic therapy is essential for the management of patients in a variety of clinical conditions, including surgery and on extracorporeal life support.

Current monitoring devices do not measure the effects of hemodynamic forces that contribute significantly to coagulation, platelet function and fibrin formation. This limits the extent to which current assays can predict clotting status in patients.

Bioengineers at the Texas A&M College of Engineering (College Station, TX, USA) have developed a biomimetic microfluidic device consisting stenosed and tortuous arteriolar vessels would analyze blood clotting under flow, while requiring a small blood volume. Blood from healthy adult donors was collected upon informed consent in 3.2% sodium citrate tubes. Platelet counts were measured using a complete blood count (CBC) machine (Hemavet, Drew Scientific Inc, Miami Lakes, FL, USA). Platelets were first separated from blood via standard centrifugation methods, and they were added back to blood to achieve required concentration (count/mL).

The team reported that the microdevice mimics tortuous blood vessels and created a diseased microenvironment in which blood may rapidly clot under flow. They showed this biomimetic blood clotting device could be used to design and monitor drugs that are given to patients who suffer from clotting disorders. The team coordinated with clinicians to test the device with pediatric patients in critical care whose heart and lungs were not working properly. These patients were in need of an extracorporeal membrane oxygenation (ECMO) machine, which provides cardiac and respiratory support in exchange of oxygen and carbon dioxide.

A common complication in ECMO is blood clotting, so patients are administered anticoagulants to prevent clotting. However, ECMO machines are also known to obliterate clotting proteins and platelets, which puts anticoagulated patients in further risk of bleeding. Anticoagulated pediatric patients on ECMO are especially prone to bleeding. Current chemically based blood clotting tests are expensive, time-consuming, can be unreliable and require a skilled technician. The team’s tortuosity based microfluidic system doesn't require expensive chemicals, is quick, with results within 10-15 minutes, uses low blood sample volume and is easy to operate.

Abhishek Jain, PhD an assistant professor and senior study author, said, “We could see several applications for the device, including critical care units and military trauma care units. It can be used in detection of clotting disorders and used in precision medicine where you would want to monitor pro-thrombotic or anti-thrombotic therapies and optimize the therapeutic approach.” The study was originally published on April 1, 2020 in the journal Scientific Reports.

Print article
BIOHIT  Healthcare OY


Industry News

view channel
Image: Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership (Photo courtesy of Randox Laboratories)

Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership

The game-changing partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) continues to alter the testing landscape and capabilities of both laboratory and non-laboratory... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.